Lurbinectedin is a novel anticancer drug that has shown promise in the treatment of various types of cancer. While there is limited information available specifically regarding the combination of lurbinectedin with immunotherapy, the available sources can provide some insights.

According to the sources, lurbinectedin is primarily used as a single agent or in combination with other chemotherapy drugs for the treatment of certain types of cancer, such as small cell lung cancer and metastatic triple-negative breast cancer [1]. It is important to note that the sources do not specifically mention the use of lurbinectedin in combination with immunotherapy.

Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer cells. It has shown significant success in various types of cancer, including melanoma, lung cancer, and bladder cancer [3]. However, the specific types of immunotherapy that work best with lurbinectedin are not mentioned in the provided sources.

To determine the most effective types of immunotherapy to combine with lurbinectedin, it would be advisable to consult with a medical professional or oncologist who can consider the specific type and stage of cancer, as well as individual patient factors. They will be able to provide personalized treatment recommendations based on the latest research and clinical trials.

In summary, while lurbinectedin has shown promise in the treatment of certain types of cancer, the available sources do not provide specific information about the types of immunotherapy that work best with lurbinectedin. Consulting with a medical professional or oncologist would be the best course of action to determine the most effective treatment plan for a specific patient.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] National Cancer Institute. Clinical Trials: Lurbinectedin. Retrieved from https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2020-09844
[3] National Center for Biotechnology Information. Immunotherapy for Cancer Treatment. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/